Moving beyond just solid dose, Recro Pharma is headed to San Diego with acquisition
Pennsylvania-based CDMO Recro Pharma is expanding to the West Coast with the acquisition of Irisys, a San Diego CDMO.
The company announced the deal Friday. Recro bought Irisys for about $50 million in cash, shares and a promissory note.
Irisys can commercially manufacture oral liquids, sterile injectables, tablets, topicals, liquid- and powder-filled capsules, ophthalmic droppers, liposomes, and nanoparticles. With the acquisition, Recro gets almost 40 clients in six countries around the world.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,200+ biopharma pros reading Endpoints daily — and it's free.